Umary USA Recalls Joint Pain Supplements Over Serious Health Risks
Umary USA has announced a nationwide recall of its dietary supplements, Unavy Ácido Hialurónico and Umovy Ácido Hialurónico, citing serious health risks due to the presence of undeclared drugs. The recall affects all lots and dates of the products, which are marketed for joint pain and arthritis relief.
According to the U.S. Food and Drug Administration (FDA), these supplements contain diclofenac, dexamethasone, and omeprazole—substances that cannot be classified as dietary supplements. Dexamethasone, a corticosteroid, poses risks such as weakened immunity and cardiovascular issues, while diclofenac can lead to severe reactions, particularly in individuals with preexisting health conditions. Omeprazole, a proton pump inhibitor, may mask serious gastric conditions.
Consumers are urged to stop using these supplements immediately and consult healthcare providers for guidance on safe discontinuation. Although no adverse reactions have been reported so far, the FDA advises those experiencing problems to report them to the FDA’s MedWatch program.
Umary USA is actively notifying customers and arranging for product returns and refunds. For more details, consumers can contact Umary USA directly via email. For further information, visit the FDA’s official recall notice.
Note: The image is for illustrative purposes only and is not the original image of the presented article.
